The Activate-Colorectal study will test the safety and efficacy of botensilimab as a standalone therapy or in combination with balstilimab for the treatment of microsatellite stable colorectal cancer, the company said.
Meanwhile, the Activate-Melanoma study will evaluate the safety and efficacy of the drug candidate as a single agent for advanced melanoma.
The company expects to launch an additional phase 2 study in pancreatic cancer later this year.